These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31530611)

  • 1. Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial.
    Newell M; Mackey JR; Bigras G; Alvarez-Camacho M; Goruk S; Ghosh S; Schmidt A; Miede D; Chisotti A; Postovit L; Baker K; Mazurak V; Courneya K; Berendt R; Dong WF; Wood G; Basi SK; Joy AA; King K; Meza-Junco J; Zhu X; Field C
    BMJ Open; 2019 Sep; 9(9):e030502. PubMed ID: 31530611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Omega-3 Supplementation on Ki-67 and VEGF Expression Levels and Clinical Outcomes of Locally Advanced Breast Cancer Patients Treated with Neoadjuvant CAF Chemotherapy: A Randomized Controlled Trial Report.
    Darwito D; Dharmana E; Riwanto I; Budijitno S; Suwardjo S; Purnomo J; Widodo I; Ghozali A; Aryandono T; Anwar SL
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):911-916. PubMed ID: 30912414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
    Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
    Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: a randomized, controlled, double-blinded clinical trial.
    de la Rosa Oliva F; Meneses García A; Ruiz Calzada H; Astudillo de la Vega H; Bargalló Rocha E; Lara-Medina F; Alvarado Miranda A; Matus-Santos J; Flores-Díaz D; Oñate-Acuña LF; Gutiérrez-Salmeán G; Ruiz García E; Ibarra A
    Nutr Hosp; 2019 Aug; 36(4):769-776. PubMed ID: 31192682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial.
    López-Neyra A; Suárez L; Muñoz M; de Blas A; Ruiz de Valbuena M; Garriga M; Calvo J; Ribes C; Girón Moreno R; Máiz L; González D; Bousoño C; Manzanares J; Pastor Ó; Martínez-Botas J; Del Campo R; Cantón R; Roy G; Menacho M; Arroyo D; Zamora J; Soriano JB; Lamas A
    Prostaglandins Leukot Essent Fatty Acids; 2020 Nov; 162():102186. PubMed ID: 33038833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines.
    Mozurkewich EL; Berman DR; Vahratian A; Clinton CM; Romero VC; Chilimigras JL; Vazquez D; Qualls C; Djuric Z
    BMC Pregnancy Childbirth; 2018 Jun; 18(1):261. PubMed ID: 29940888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for assessing whether cognition of preterm infants <29 weeks' gestation can be improved by an intervention with the omega-3 long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA): a follow-up of a randomised controlled trial.
    Gould JF; Makrides M; Sullivan TR; Anderson PJ; Gibson RA; Best KP; McPhee AJ; Doyle LW; Opie G; Travadi J; Cheong J; Davis PG; Sharp M; Simmer K; Collins CT
    BMJ Open; 2021 Feb; 11(2):e041597. PubMed ID: 33550243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol.
    Engineer R; Patkar S; Lewis SC; Sharma AD; Shetty N; Ostwal V; Ramaswamy A; Chopra S; Agrawal A; Patil P; Mehta S; Goel M
    BMJ Open; 2019 Jun; 9(6):e028147. PubMed ID: 31253621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.
    Nobili V; Bedogni G; Alisi A; Pietrobattista A; Risé P; Galli C; Agostoni C
    Arch Dis Child; 2011 Apr; 96(4):350-3. PubMed ID: 21233083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Dieci MV; Frassoldati A; Generali D; Bisagni G; Piacentini F; Cavanna L; Cagossi K; Puglisi F; Michelotti A; Berardi R; Banna G; Goubar A; Ficarra G; Griguolo G; Conte P; Guarneri V
    Breast Cancer Res Treat; 2017 Jun; 163(2):295-302. PubMed ID: 28289852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.